Lumigan (Bimatoprost 0.01%) – Townsville, North Queensland, Australia (2026)
Visit
Website: unnatipharmax.com
Phone: +91 82650 41513
Email: Unnatipharmax@gmail.com
PRODUCT NAME
Brand Name: Lumigan
Generic Name: Bimatoprost Ophthalmic Solution 0.01%
Strength: 0.01% w/v
Dosage Form: Sterile Ophthalmic Solution (Eye Drops)
Therapeutic Category: Prostaglandin Analogue
PRODUCT DETAILS
Lumigan contains Bimatoprost 0.01%, a prostaglandin analogue used to lower elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. By improving the natural drainage of fluid from the eye, it helps reduce IOP and supports the management of glaucoma when used as prescribed.
It is commonly prescribed for:
- Open-Angle Glaucoma
- Ocular Hypertension
- Elevated Intraocular Pressure (IOP)
- Long-term Glaucoma Management
Use only under the supervision of a qualified healthcare professional.
PRODUCT SPECIFICATION
| Brand Name | Lumigan |
| Generic Name | Bimatoprost |
| Strength | 0.01% w/v |
| Dosage Form | Ophthalmic Solution (Eye Drops) |
| Route | Ophthalmic Use |
| Therapeutic Class | Prostaglandin Analogue |
| Packaging | Sterile Bottle |
| Storage | Store below 25°C. Protect from light. |
| Prescription | Required |
| Manufactured In | India |
| Export Availability | Worldwide (where legally permitted) |
KEY FEATURES
- Contains Bimatoprost 0.01%
- Helps lower elevated intraocular pressure
- Used in the treatment of open-angle glaucoma and ocular hypertension
- Sterile ophthalmic solution for daily use as prescribed
- Supports long-term glaucoma management
- Manufactured in WHO-GMP compliant facilities
- High-quality formulation for international markets
- Available for retail, wholesale, and bulk export
- Secure packaging for worldwide shipping
- Competitive export pricing
INDUSTRY UPDATE
The global ophthalmology market continues to expand in 2026 due to the increasing prevalence of glaucoma, an aging population, and greater awareness of routine eye health screenings. Prostaglandin analogue eye drops, including Bimatoprost, remain a standard first-line treatment option for reducing intraocular pressure in eligible patients.
Current industry trends include:
- Rising demand for effective glaucoma management therapies
- Increased adoption of early glaucoma screening and diagnosis
- Growth of teleophthalmology and remote eye care services
- Greater availability of high-quality generic ophthalmic medications
- Continued emphasis on treatment adherence and regular eye pressure monitoring to help preserve vision and improve long-term patient outcomes.

FAQ 1: How does Townsville's role as North Queensland's ophthalmology hub affect glaucoma access for remote communities?

FAQ 2: How does Townsville's Aboriginal and Torres Strait Islander glaucoma burden create specific Lumigan demand and access challenges?

FAQ 3: What is the difference between Lumigan 0.01% and Careprost 0.03% — which is appropriate for Townsville's glaucoma patients?

FAQ 4: How does Townsville's extreme tropical climate affect Lumigan storage and glaucoma management?

FAQ 5: How does Townsville's RAAF Townsville and Lavarack Barracks military community engage with Lumigan for glaucoma?
Website
Email Id
Contact Number
+91-8265041513
Lumigan-Bimatoprost-0.01-Townsville